Ronan Hsieh, MD
Hematology & Oncology · Seattle, WANPI 1457880031
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $47,965 of the $64,589 with a category attached, or 74.3%. 19 manufacturers reported payments, led by Incyte Corporation at 43.3% of the total. 2025 is the largest year on record at $60,846, more than ten times the $98 reported in 2019. Among hematology & oncology clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 108 payments — averaging $598.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$28K
- Beone Medicines USA, Inc.$25K
- AstraZeneca$5K
- E.r. Squibb & Sons, L.L.C.$2K
- Merck$2K
- Johnson & Johnson$545
- plus $2K from 13 others
What the payments were for
- Consulting fees$4,6207%
- Speaking & faculty fees$47,96574%
- Travel & lodging$7,62412%
- Food & beverage$3,8596%
- Education$5211%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 35 | $27,990 |
| Beone Medicines USA, Inc. | 22 | $25,472 |
| AstraZeneca | 8 | $5,496 |
| E.r. Squibb & Sons, L.L.C. | 3 | $1,781 |
| Merck | 9 | $1,562 |
| Johnson & Johnson(2 entities) | 6 | $545 |
| Amgen | 7 | $355 |
| Lilly USA, LLC | 3 | $199 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $188 |
| Eisai Inc. | 2 | $143 |
| Pfizer | 1 | $135 |
| Daiichi Sankyo Inc. | 2 | $130 |
| AbbVie | 1 | $125 |
| Foundation Medicine, Inc. | 1 | $124 |
| Rigel Pharmaceuticals, Inc. | 1 | $106 |
| Jazz Pharmaceuticals Inc. | 1 | $98 |
| Tempus AI, Inc | 1 | $62 |
| Stemline Therapeutics Inc. | 1 | $39 |
| Janssen Research & Development, LLC | 1 | $38 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$64,589 in reported general payments places this provider in the 90th percentile of 349 hematology & oncology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prochlorperazine Maleate | 30 | $579 |
| LoperamideLoperamide Hcl | 26 | $391 |
| Ondansetron Hcl | 25 | $379 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 30 | $336 |
| Oxycodone Hcl | 13 | $158 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Seattle
- John PesandoSeattle$15.7M
- Jill JohnsenSeattle$991K
- Fengting YanSeattle$841K
- John PagelSeattle$725K
- Lawrence FongSeattle$546K
- Langdon MillerSeattle$457K
- Mazyar ShadmanSeattle$226K
- Catherine LeeSeattle$199K
- Celestia HiganoSeattle$164K
- Ryan CassadaySeattle$151K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.